PDCD1 and neoplasm: Overall, a clear overall survival (OS) and PFS advantage was observed in the platinum-based chemotherapy plus anti-PD-1 or anti-PD-L1 groups compared to chemotherapy alone, irrespective of tumor PD-L1 level [53].